Understanding PT-141 / Bremelanotide
The source distinguishes labelled Vyleesi use for a defined female HSDD population from male, intranasal, and other off-label contexts. Evidence from one population or route does not establish equivalent effects for another. Approval of a finished autoinjector also does not validate research-vial preparations.
Compound Name
PT-141, also known as bremelanotide
Labelled Product Context
Vyleesi is discussed for premenopausal women with acquired, generalized HSDD.
Labelled Route
Subcutaneous use with the finished Vyleesi autoinjector, as described in the source.
Other Reported Contexts
Male erectile-dysfunction research, intranasal study arms, and other off-label contexts are discussed separately.
Important Safety Concerns
Nausea, flushing, headache, pigmentation changes, and blood-pressure effects are listed in the source.
Key Limitation
Findings from the labelled female population do not establish male performance-enhancement benefits or equivalence for intranasal use.
Labelled Use Is Not the Same as Research-Vial Use
The source separates the finished Vyleesi autoinjector from research-vial preparations. Approval of the finished product does not validate unapproved formulations, routes, or preparation methods. Evidence should be interpreted within the population and route actually studied.
Reported Bremelanotide Use Contexts
The source describes labelled Vyleesi use for a defined premenopausal female HSDD population and separately mentions intranasal male erectile-dysfunction study arms. These contexts are not interchangeable, and the research figures do not establish personal-use instructions.
SC example
Per administration
Frequency
Daily total
Reported cycle
Labelled Vyleesi Context
The source reports a labelled dose of 1.75 mg subcutaneously using Vyleesi.
The source states a maximum of once in 24 hours.
Maximum one labelled administration in 24 hours, according to the source; not a daily treatment recommendation beyond the product label.
The source describes a 24-week on-demand trial period and a 52-week extension. These are study durations, not instructions to use continuously.
Intranasal Male ED Study Arms
The source reports intranasal study arms of 7.5–20 mg.
Not specified in the compound summary.
Not specified in the compound summary.
Trial context is mentioned, but the compound summary does not specify the duration of these intranasal arms.
Other Off-Label / Research Contexts
Not specified as a single amount; the source refers broadly to male, nasal, and other off-label contexts.
Not specified in the source summary.
Not specified in the compound summary.
Not specified in the source summary.
Per administration
The source reports a labelled dose of 1.75 mg subcutaneously using Vyleesi.
Frequency
The source states a maximum of once in 24 hours.
Daily total
Maximum one labelled administration in 24 hours, according to the source; not a daily treatment recommendation beyond the product label.
Reported cycle
The source describes a 24-week on-demand trial period and a 52-week extension. These are study durations, not instructions to use continuously.
Intranasal Male ED Study Arms
Per administration
The source reports intranasal study arms of 7.5–20 mg.
Frequency
Not specified in the compound summary.
Daily total
Not specified in the compound summary.
Reported cycle
Trial context is mentioned, but the compound summary does not specify the duration of these intranasal arms.
Other Off-Label / Research Contexts
Per administration
Not specified as a single amount; the source refers broadly to male, nasal, and other off-label contexts.
Frequency
Not specified in the source summary.
Daily total
Not specified in the compound summary.
Reported cycle
Not specified in the source summary.
The source reports Vyleesi as 1.75 mg SC at least 45 minutes beforehand, with a maximum of once per 24 hours and eight times per month. This applies to the labelled product context and population. The intranasal 7.5–20 mg figures are research-study arms, not an approved nasal regimen.
Do Not Treat Research Arms as Approved Dosing
Labelled Vyleesi use is population-specific. Intranasal male ED study arms and other off-label contexts must not be presented as equivalent to the labelled product. Approval of the finished autoinjector does not validate research-vial preparations or alternative routes.
Safety Concerns & Contraindications
The source identifies blood-pressure effects and nausea as important safety considerations. It also lists flushing, headache, and pigmentation changes and notes that population restrictions matter.
Product Storage & Monitoring Context
Finished Vyleesi Product
The source states that Vyleesi room-temperature storage differs from the refrigeration reported for research-vial material. It does not provide detailed room-temperature storage limits in this summary.
Research-Vial Storage
The source distinguishes research-vial refrigeration from finished-product storage but does not specify a complete research-vial storage protocol in this compound summary.
Monitoring Context
The source identifies blood pressure, nausea, and pigmentation as relevant safety considerations.
Product & Route Limitations
Storage requirements depend on the specific product. Do not transfer storage assumptions from the finished autoinjector to research-vial preparations. Refer to the applicable approved product information.
Bremelanotide Concentration Calculation Examples
The source provides independently recomputed examples using different assumed amounts and final volumes. These are arithmetic examples only and are not instructions for preparing or administering a product.
Amount (mg)
Final volume (mL)
Concentration (mg/mL)
Per 1 U (mcg)
Per 10 U (mcg)
10 mg
1 mL
10 mg/mL
100 mcg
1000 mcg
10 mg
2 mL
5 mg/mL
50 mcg
500 mcg
Concentration (mg/mL)
10 mg/mL
Concentration (mg/mL)
5 mg/mL
The source also lists 10 mg in 2.5 mL = 4 mg/mL, 40 mcg per 1 U, and 400 mcg per 10 U. U refers to a U-100 volume marking, where 1 U = 0.01 mL. These are arithmetic examples only—not mixing or administration instructions. For a blend, total mass does not represent the amount of each individual ingredient.
What the Clinical Research Reports
The source reports that the RECONNECT programme enrolled roughly 1,200 women and improved sexual-desire and distress endpoints over 24 weeks. These findings relate to the studied female HSDD population and do not establish equivalent outcomes in men or with intranasal use.
Women in RECONNECT
The source reports that the RECONNECT programme enrolled roughly 1,200 women. The participant count alone does not establish effectiveness outside the studied population.
Reported Trial Period
The source reports improvements in sexual-desire and distress endpoints over 24 weeks in the RECONNECT programme. These results should be interpreted within the trial’s defined population and study design.
Male & Intranasal Equivalence
The source cautions that the female HSDD findings do not establish male performance-enhancement benefits or equivalence for intranasal use.
Labelled Use & Research Limitations
Approval Applies to a Specific Product and Population
The source distinguishes labelled Vyleesi use for a defined population of premenopausal women with acquired, generalized HSDD from male, nasal, and other off-label contexts. Approval of the finished autoinjector does not validate research-vial preparations or alternative routes. Clinical findings in the studied population do not establish equivalent benefits in other populations.
This page is for educational and research-reference purposes only. It is not personal medical advice. Product approval, study findings, safety information, and storage requirements are product- and context-specific. Consult a qualified healthcare professional and the applicable official product information for medical questions.
